# HIPEC at interval cytoreductive surgery

Source: https://onco.cc/pairings/hipec-at-interval-surgery/  
OnCo record `hipec-at-interval-surgery` (Pairing). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Heated intraperitoneal cisplatin during interval surgery, after neoadjuvant chemotherapy, extends survival in stage III disease.

## Summary

Hyperthermic intraperitoneal chemotherapy delivered with platinum during interval cytoreductive surgery, after neoadjuvant chemotherapy for stage III ovarian cancer, is a combination pairing that extended survival in the phase 3 OVHIPEC-1 trial without additional major complications, and the benefit was confirmed at ten years of follow-up; a Korean trial is supportive. The rationale is direct high-dose exposure of residual microscopic peritoneal disease at the moment of maximal cytoreduction, with hyperthermia enhancing platinum uptake into tumour cells. The benefit appears specific to the interval-surgery setting. HIPEC at primary surgery is still being tested in OVHIPEC-2.

## Fields

- Kind: Pairing
- Last checked: 2026-09-07
- Pairs: HIPEC / PIPAC (intraperitoneal chemotherapy) + Carboplatin
- Type: combination
- Rationale: Direct high-dose exposure of residual microscopic peritoneal disease at the moment of maximal cytoreduction, with hyperthermia enhancing platinum uptake.
- Evidence: Phase 3 with OS benefit; one supportive Korean trial.

## Sources

- ClinicalTrials.gov NCT00426257: OVHIPEC-1: https://clinicaltrials.gov/study/NCT00426257

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- technologies: [HIPEC / PIPAC (intraperitoneal chemotherapy)](https://onco.cc/technologies/hipec/)
- trials: [OVHIPEC-1](https://onco.cc/trials/ovhipec-1/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/)

---
JSON: https://onco.cc/api/v1/entities/hipec-at-interval-surgery.json